Description

FOXO4-DRI is a novel senolytic peptide developed to combat cellular senescence, a biological process where cells stop dividing and enter a state of irreversible growth arrest. These senescent cells accumulate in tissues over time and secrete a range of pro-inflammatory cytokines, chemokines, and proteases, collectively known as the Senescence-Associated Secretory Phenotype (SASP). The SASP is a key driver of chronic inflammation and is implicated in numerous age-related pathologies, including cardiovascular disease, neurodegeneration, and frailty.

The mechanism of action for FOXO4-DRI is highly specific. In senescent cells, the transcription factor FOXO4 is sequestered in the nucleus, where it binds to the tumor suppressor protein p53. This FOXO4-p53 interaction prevents the senescent cells from undergoing apoptosis (programmed cell death), allowing them to persist and cause damage.

FOXO4-DRI is a D-Retro-Inverso peptide, a modified structure that makes it resistant to degradation by proteases, thereby increasing its stability and bioavailability in the body. It acts as a competitive antagonist by binding to p53 in the same region that FOXO4 would, effectively disrupting the protective FOXO4-p53 complex. Once this interaction is broken, p53 is free to initiate the apoptotic cascade, leading to the selective elimination of senescent cells.

Preclinical studies in naturally aged and progeroid (rapidly aging) mice have demonstrated that administration of FOXO4-DRI can restore tissue homeostasis, improve renal function, increase physical activity, and enhance hair density, effectively reversing certain age-related phenotypes without observable side effects on healthy tissues. These findings position FOXO4-DRI as a promising therapeutic candidate for targeting the root causes of age-related decline and improving overall healthspan.